Ron H.J. Mathijssen

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Ron H.J. Mathijssen, R J van Alphen, Jaco J. Verweij et al. · PubMed · 2001 · 752 citations

Cpt-11 Belongs, Chemoprevention Strategy, Pharmacotherapy +18

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Amit M. Oza, David Cibula, Ana Oaknin Benzaquen et al. · The Lancet Oncology · 2014 · 540 citations

Medicine, Randomised Phase 2, Gynecology +6

Effects of St. John's Wort on Irinotecan Metabolism

Ron H.J. Mathijssen · JNCI Journal of the National Cancer Institute · 2002 · 446 citations · Full text

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 403 citations · Full text

Medicine, Prospective Safety Analysis, Cancer Management +9

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

Kelly K. Filipski, Ron H.J. Mathijssen, Torben Stamm Mikkelsen et al. · Clinical Pharmacology & Therapeutics · 2009 · 393 citations · Full text